Tags

Type your tag names separated by a space and hit enter

NG-nitro-L-arginine methyl ester attenuates the maintenance and expression of methamphetamine-induced behavioral sensitization and enhancement of striatal dopamine release.
J Pharmacol Exp Ther. 1996 Jun; 277(3):1424-30.JP

Abstract

We examined the roles of nitric oxide (NO) in methamphetamine (MAP)-induced behavioral sensitization and enhancement of striatal dopamine (DA) release using both in vivo and in vitro methods. Repeated administration of MAP produced augmentation of MAP-induced locomotor activity after 3-day withdrawal of MAP and an enhancement of MAP-evoked DA release from striatal slices after 6-day withdrawal. When the NO synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L- NAME) was administered only during the period of MAP withdrawal, the behavioral sensitization and enhancement of DA release were attenuated significantly. In contrast, NG-nitro-D- arginine methyl ester, an inactive isomer of L-NAME, exhibited no such effect. When L-NAME was administered acutely before the challenge injection of MAP, behavioral sensitization was also attenuated only when the dose of L-NAME was high. Coadministration of L-NAME with MAP did not block the development of sensitization to MAP. We also examined whether MAP-induced behavioral sensitization and enhancement of DA release could be observed in vivo in a microdialysis experiment. Challenge injection of MAP caused marked enhancement of DA release in MAP-sensitized rats compared with saline-treated controls corresponding to robust augmentation of locomotor activity. When L-NAME was injected during the MAP withdrawal period, the enhancement of DA release and locomotor activity induced by challenge injection of MAP were attenuated. These results suggest that NO production plays a role in the maintenance (expression) of MAP-induced behavioral sensitization and enhancement of DA release but not in the development of these effects.

Authors+Show Affiliations

Department of Pharmacology, Faculty of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

8667206

Citation

Inoue, H, et al. "NG-nitro-L-arginine Methyl Ester Attenuates the Maintenance and Expression of Methamphetamine-induced Behavioral Sensitization and Enhancement of Striatal Dopamine Release." The Journal of Pharmacology and Experimental Therapeutics, vol. 277, no. 3, 1996, pp. 1424-30.
Inoue H, Arai I, Shibata S, et al. NG-nitro-L-arginine methyl ester attenuates the maintenance and expression of methamphetamine-induced behavioral sensitization and enhancement of striatal dopamine release. J Pharmacol Exp Ther. 1996;277(3):1424-30.
Inoue, H., Arai, I., Shibata, S., & Watanabe, S. (1996). NG-nitro-L-arginine methyl ester attenuates the maintenance and expression of methamphetamine-induced behavioral sensitization and enhancement of striatal dopamine release. The Journal of Pharmacology and Experimental Therapeutics, 277(3), 1424-30.
Inoue H, et al. NG-nitro-L-arginine Methyl Ester Attenuates the Maintenance and Expression of Methamphetamine-induced Behavioral Sensitization and Enhancement of Striatal Dopamine Release. J Pharmacol Exp Ther. 1996;277(3):1424-30. PubMed PMID: 8667206.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - NG-nitro-L-arginine methyl ester attenuates the maintenance and expression of methamphetamine-induced behavioral sensitization and enhancement of striatal dopamine release. AU - Inoue,H, AU - Arai,I, AU - Shibata,S, AU - Watanabe,S, PY - 1996/6/1/pubmed PY - 1996/6/1/medline PY - 1996/6/1/entrez SP - 1424 EP - 30 JF - The Journal of pharmacology and experimental therapeutics JO - J Pharmacol Exp Ther VL - 277 IS - 3 N2 - We examined the roles of nitric oxide (NO) in methamphetamine (MAP)-induced behavioral sensitization and enhancement of striatal dopamine (DA) release using both in vivo and in vitro methods. Repeated administration of MAP produced augmentation of MAP-induced locomotor activity after 3-day withdrawal of MAP and an enhancement of MAP-evoked DA release from striatal slices after 6-day withdrawal. When the NO synthase (NOS) inhibitor NG-nitro-L-arginine methyl ester (L- NAME) was administered only during the period of MAP withdrawal, the behavioral sensitization and enhancement of DA release were attenuated significantly. In contrast, NG-nitro-D- arginine methyl ester, an inactive isomer of L-NAME, exhibited no such effect. When L-NAME was administered acutely before the challenge injection of MAP, behavioral sensitization was also attenuated only when the dose of L-NAME was high. Coadministration of L-NAME with MAP did not block the development of sensitization to MAP. We also examined whether MAP-induced behavioral sensitization and enhancement of DA release could be observed in vivo in a microdialysis experiment. Challenge injection of MAP caused marked enhancement of DA release in MAP-sensitized rats compared with saline-treated controls corresponding to robust augmentation of locomotor activity. When L-NAME was injected during the MAP withdrawal period, the enhancement of DA release and locomotor activity induced by challenge injection of MAP were attenuated. These results suggest that NO production plays a role in the maintenance (expression) of MAP-induced behavioral sensitization and enhancement of DA release but not in the development of these effects. SN - 0022-3565 UR - https://www.unboundmedicine.com/medline/citation/8667206/NG_nitro_L_arginine_methyl_ester_attenuates_the_maintenance_and_expression_of_methamphetamine_induced_behavioral_sensitization_and_enhancement_of_striatal_dopamine_release_ L2 - https://jpet.aspetjournals.org/cgi/pmidlookup?view=long&pmid=8667206 DB - PRIME DP - Unbound Medicine ER -